BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 29
• 30

• 

  What Qualities of a Good Mentor to Look For

  Moving forward in your career requires having a great mentor. Here are some qualities of a good mentor that you should look for before choosing one for yourself.

  April 24, 2018

   · 

  3 min read

   · 

  Porschia Parker
• 

  Drug Development

  Biogen’s First Quarter Driven by MS Drugs and Spinraza

  Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.

  April 24, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Eli Lilly’s Arthritis Drug Gets Mixed Recommendation, But Reports Strong Quarter

  Last week, the FDA’s advisory committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis expressed safety concerns. Not surprisingly, the Arthritis Advisory Committee’s recommendation yesterday was mixed, split right along safety concerns.

  April 24, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  BioForest

  Companies Showcase Good News for Patients at AAN

  This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.

  April 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Cedilla Therapeutics Launches with $56.2 Million

  Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.

  April 24, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  BioCapital

  When Failure Feeds on Itself

  Sometimes it feels like biotech’s successes and failures come in waves—even when it involves entirely unrelated clinical programs. This past month has had many in industry feeling like they’re underwater.

  April 24, 2018

   · 

  3 min read

   · 

  Karl Thiel
• 

  Business

  New Sanofi R&D Boss Marks Yet Another High-Profile Industry Executive Change

  Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.

  April 24, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion

  Takeda Pharmaceutical has come back with an improved bid for Shire, making it the fifth round of talks.

  April 24, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Company

  Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.

  April 24, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Are Biotech Stocks Undervalued Right Now?

  It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.

  April 24, 2018

   · 

  2 min read

   · 

  Karl Thiel